



**Office of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda**

March 24, 2009 6:30 – 9:00 p.m. **NOTE NEW DATE**

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**
(Public Comment Prior to Board Action)

- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**

- 4. Medical Director Update** **7:15 - 7:25**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meeting** **7:25 - 7:30**
 - Anti-psychotics: Atypicals and Combinations (Seroquel XR[®])

- 6. Clinical Update: Drug Reviews (Abbreviated)** **7:30 – 7:40**
(Public comment prior to Board action)
 - Alvesco[®] (ciclesonide) Inhaler
 - Nplate[®] (romiplostim) Injection

- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:40 – 7:50**
(Public comment prior to Board action)
 - New to Market Drugs
 - Cosmetic Drugs/Drugs for Hair Growth

- 8. Drug Classes – Annual Review** **7:50 – 8:40**
(Public comment prior to Board action)
Class review documents available on OVHA web site 03/24/09 @ 12 Noon
Anemia Medications – Erythropoetins
Alzheimer’s Medications
 - Cholinesterase Inhibitors
 - NMDA Receptor Antagonist**Migraine – Triptans**
Multiple Sclerosis Injectables
Parkinson’s Medications
 - COMT Inhibitors
 - Dopamine Precursor/Dopa Decarboxylase Inhibitors
 - Dopamine Agonists

- MAO-B Inhibitors
- Other – Stalevo[®] (carbidopa/levodopa/entacapone)

Skeletal Muscle Relaxants

Urinary Antispasmodics

- | | |
|---|--------------------|
| 9. RetroDUR | 8:40 - 8:50 |
| <ul style="list-style-type: none">▪ Desmopressin▪ Migraine/Triptans | |
| 10. New Drug Product Plan Exclusions (Consent Agenda Topic) | 8:50 - 8:50 |
| 11. Updated New-to-Market Drug Monitoring Log | 8:50 - 8:50 |
| 12. General Announcements | 8:50 - 9:00 |
| Selected FDA Safety Alerts | |
| <ul style="list-style-type: none">▪ Raptiva[®] – PML▪ Zonisamide – metabolic acidosis▪ Metoclopramide – tardive dyskinesia▪ Risk Evaluation for Opioids | |
| 13. Adjourn | 9:00 |